Provided by Tiger Fintech (Singapore) Pte. Ltd.

BriaCell Therapeutics Corp.

0.7400
+0.00100.14%
Post-market: 0.7200-0.0200-2.70%19:57 EDT
Volume:462.56K
Turnover:340.11K
Market Cap:13.89M
PE:-0.11
High:0.7449
Open:0.7400
Low:0.7200
Close:0.7390
52wk High:29.40
52wk Low:0.6100
Shares:18.78M
Float Shares:16.23M
Volume Ratio:0.70
T/O Rate:2.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.9195
EPS(LYR):-4.3678
ROE:-688.17%
ROA:-131.54%
PB:1.12
PE(LYR):-0.17

Loading ...

BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

GlobeNewswire
·
Aug 13

BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance

TIPRANKS
·
Aug 06

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

GlobeNewswire
·
Jul 31

BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents

GlobeNewswire
·
Jul 29

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

GlobeNewswire
·
Jul 25

BriaCell Therapeutics Closes $15 million Public Offering

MT Newswires Live
·
Jul 17

BriaCell Therapeutics Announces Closing of $15 million Public Offering

GlobeNewswire
·
Jul 17

BriaCell Therapeutics Slide After Equity Offer

Dow Jones
·
Jul 16

BriaCell sinks 61% to 79c after pricing 12M unit offering at $1.25

TIPRANKS
·
Jul 16

BriaCell says $15M unit offering prices at $1.25 per unit

TIPRANKS
·
Jul 16

BriaCell Adds Mayo Clinic to Phase 3 Study in Metastatic Breast Cancer

GlobeNewswire
·
Jul 15

BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer

GlobeNewswire
·
Jul 11

BriaCell’s Bria-IMT Shows Promising Results in Advanced Breast Cancer Treatment

TIPRANKS
·
Jul 10

BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient

GlobeNewswire
·
Jul 10

BriaCell says patient achieves sustained complete resolution of lung metastasis

TIPRANKS
·
Jul 09

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer

GlobeNewswire
·
Jul 08

BriaCell Expands Phase 3 Cancer Study with New Clinical Sites

TIPRANKS
·
Jul 02

BriaCell reports iDSMB has completed third scheduled safety data review

TIPRANKS
·
Jun 24

BriaCell Reports Increased Losses in Latest Financials

TIPRANKS
·
Jun 18

BriaCell Therapeutics Q3 EPS $(1.64) Down From $1.61 YoY

Benzinga
·
Jun 17